Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide
Shannon R. McCurdy(Hospital of the University of Pennsylvania), Mary Eapen(Medical College of Wisconsin), Maxim Norkin(University of Florida Health), Mehdi Hamadani(Medical College of Wisconsin), Edmund K. Waller(Emory University), Álvaro Urbano-Ispizúa(University of St.Gallen), Asad Bashey, Monzr M. Al Malki(City of Hope), Daniel A. Keesler(Medical College of Wisconsin), Rizwan Romee(Washington University in St. Louis), Ephraim J. Fuchs(Johns Hopkins University), Sameh Gaballa(Johns Hopkins Hospital), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Andrew St. Martin(Johns Hopkins Hospital), Ran Reshef(Abramson Cancer Center), Melhem Solh(Johns Hopkins Hospital), Mei-Jie Zhang(Medical College of Wisconsin), Vanderson Rocha(Fundação Pró-Sangue Hemocentro de São Paulo)
Cited by 96
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783